信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01801 信达生物

开市前 11-22 09:08:23

37.800

-0.700

-1.82%

最高37.800	最低37.800	成交量0.00
今开37.800	昨收38.500	日振幅0.00%
总市值616.54亿	流通市值616.54亿	总股本16.31亿
成交额0.00	换手率0.00%	流通股本16.31亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01801","market":"HK","secType":"STK","nameCN":"信达生物","latestPrice":37.8,"timestamp":1732237703257,"preClose":38.5,"halted":0,"volume":0,"delay":0,"floatShares":1631045869,"shares":1631045869,"eps":-0.70692754,"marketStatus":"开市前","marketStatusCode":1,"change":-0.7,"latestTime":"11-22 09:08:23","open":37.8,"high":37.8,"low":37.8,"amount":0,"amplitude":0,"askPrice":37.8,"askSize":6000,"bidPrice":37.8,"bidSize":6000,"shortable":3,"etf":0,"ttmEps":-0.857198331003728,"exchange":"SEHK","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732239000000},"adr":0,"listingDate":1540915200000,"adjPreClose":38.5,"openAndCloseTimeList":[[1732239000000,1732248000000],[1732251600000,1732262400000]],"volumeRatio":0,"impliedVol":0.6344,"impliedVolPercentile":0.8381,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"INB.HK"},"requestUrl":"/m/hq/s/01801","defaultTab":"news","newsList":[{"id":"2485720483","title":"港股异动 | 信达生物(01801)再涨超3%  瑞银预计GLP-1将显著渗透减肥及第二型糖尿病市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2485720483","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485720483?lang=zh_cn&edition=full","pubTime":"2024-11-21 10:31","pubTimestamp":1732156261,"startTime":"0","endTime":"0","summary":"GLP-1的临床测试结果及正面回馈，料显著渗透减肥市场及第二型糖尿病市场，该药在后者已有14%市占率。该行预测，信达生物玛仕度肽料在2034年取得中国GLP-1市场18%的市占率，基于该药的三项优势，包括预期期将在明年上半年为首个双目标GLP-1药物获准用于减肥用途，临床测试展示良好效用及安全性，以及公司强劲的商业化能力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1213850.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1589","01801","LU2328871848.SGD","BK1161","BK1583","BK4590","LU2488822045.USD","LU1969619763.USD","BK4144","GLP"],"gpt_icon":0},{"id":"2485102174","title":"【特约大V】邓声兴：市场缺乏焦点下，大市好淡拉锯","url":"https://stock-news.laohu8.com/highlight/detail?id=2485102174","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485102174?lang=zh_cn&edition=full","pubTime":"2024-11-21 09:22","pubTimestamp":1732152146,"startTime":"0","endTime":"0","summary":"大市成交额1146亿元。加密货币“一哥”比特币连续两日破顶，一度扬升3.8%，高见94962美元。MicroStrategy计划增发可换股票据以购买更多比特币，股价抽升10.1%，市值突破1000亿美元。市场缺乏焦点下，大市好淡拉锯。另外，其他收入6.09亿元，较去年同期增加23.7%。凭藉有效的获客策略和卓越的运营能力，集团进一步巩固了在中国大众市场的立足点。截至2024年9月30日，集团在居住于中国非一线城市的注册用户占注册用户总数的87%以上。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/NzE1NDA5NTM3ODk1OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/NzE1NDA5NTM3ODk1OQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1948128","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0278937759.USD","09439","BK1516","BK1611","BTC.USD.CC","BK1589","LU1115378108.SGD","BK1095","BK4594","SG9999001226.SGD","BK4601","BK1164","83042","BTC.USD.HKCC","SG9999001093.SGD","03439","BK4585","LU0315179316.USD","BK4588","03008","09008","BK1161","03042","01801","02105","BK1609","LU0640798160.USD","LU1969619763.USD","SGXZ90724238.SGD","00780","09042","LU2460026573.USD","LU2488822045.USD","BK1612","BK1583","LU2328871848.SGD","01357","SG9999001051.SGD","BK1604"],"gpt_icon":1},{"id":"2485400311","title":"“减肥神药”诺和盈深圳首张处方开出 同一赛道创新药企信达生物昨上涨8.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2485400311","media":"深圳商报","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485400311?lang=zh_cn&edition=full","pubTime":"2024-11-21 01:27","pubTimestamp":1732123668,"startTime":"0","endTime":"0","summary":"11月17日，诺和诺德宣布，减重版司美格鲁肽（商品名：诺和盈）正式在国内商业化上市。11月19日，记者获悉，减重版司美格鲁肽在中山大学附属第八医院开出深圳首张处方，也是广东首批处方。中山大学附属第八医院内分泌科主任沈云峰教授表示，减重版司美格鲁肽通过增加饱腹感从而降低食欲，同时降低饥饿感和预期摄食达到减重效果，并为患者带来超越减重的多重健康获益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411213245839812.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1969619763.USD","LU2488822045.USD","LU2328871848.SGD","BK1589","BK1583","BK1161","01801","BK1574","06978"],"gpt_icon":1},{"id":"2484887160","title":"北水动向|北水成交净买入55.71亿 内资加仓信达生物(01801)近3亿 全天抛售招商银行(03968)","url":"https://stock-news.laohu8.com/highlight/detail?id=2484887160","media":"智通财经","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484887160?lang=zh_cn&edition=full","pubTime":"2024-11-20 17:52","pubTimestamp":1732096322,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，11月20日港股市场，北水成交净买入55.71亿港元，其中港股通(沪)成交净买入30.13亿港元，港股通(深)成交净买入25.59亿港元。北水净买入最多的个股是美团-W、信达生物、腾讯。消息面上，美团拟于11月29日举行董事会会议批准第三季度业绩。信达生物获净买入2.8亿港元。招商银行遭净卖出3.75亿港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1213510.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0880133367.SGD","BK1575","600036","LU1781817850.SGD","LU1997245177.USD","LU0106252389.USD","LU1188198961.HKD","BK0028","LU2097828631.EUR","LU0359201885.HKD","LU0650527681.SGD","03968","LU2097828805.USD","LU0572944931.SGD","03143","LU0865486749.SGD","IE00BVYPNP33.GBP","LU1048588211.SGD","LU0516422952.EUR","BK1507","LU0634319403.HKD","LU0048597586.USD","LU0823426480.USD","LU0048580855.USD","LU2476274308.USD","LU0348735423.USD","MPNGY","06682","LU0541501648.USD","LU0039217434.USD","SGXZ49509284.SGD","SG9999002828.SGD","LU0348816934.USD","LU0541502299.USD","LU0463099449.HKD","LU1688375341.USD","LU0067412154.USD","LU2778985437.USD","BK1589","01801","LU0431992006.USD","LU1655091616.SGD","LU1242518857.USD","LU0244354667.USD","LU0455707207.USD","LU0251144936.SGD","LU2399975544.HKD","LU0269904917.USD","LU1211504680.USD","03690"],"gpt_icon":0},{"id":"2484090162","title":"南向资金今日大幅净买入55.71亿元。港股通（沪）方面，腾讯控股、美团-W分别获净买入3.03亿港元、2.9亿港元；小米集团-W净卖出额居首，金额为0.","url":"https://stock-news.laohu8.com/highlight/detail?id=2484090162","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484090162?lang=zh_cn&edition=full","pubTime":"2024-11-20 17:39","pubTimestamp":1732095590,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU1044876610.USD","01810","LU0499858438.USD","LU2362541513.USD","LU0140636845.USD","LU0043850808.USD","IE00BVYPNP33.GBP","TCEHY","IE0003851619.USD","LU1770034418.SGD","IE00B0169L03.USD","01801","LU0589944569.HKD","07226","IE00B8L5B284.USD","LU1008478684.HKD","HSCEI","HSTECH","LU0196878994.USD","SG9999001689.USD","600036","00700","BK0028","LU0882747503.HKD","LU1568876251.USD","LU0228367735.SGD","03690","80700","IE0008368742.USD","IE00BZ08YT58.USD","MPNGY","LU0143863198.USD","LU0327786744.USD","LU0516422952.EUR","BK1521","HTCD.SI","LU2488822045.USD","BK1233","LU0107464264.USD","LU1188198961.HKD","YANG","LU0149534421.HKD","03968","LU1725190679.HKD","03143","XIACY","SG9999001069.SGD","81810","LU2580892862.HKD","LU1439103000.SGD"],"gpt_icon":0},{"id":"2484683741","title":"信达生物(01801)出现大手买入14.45万股，成交价$38.8，涉资560.66万","url":"https://stock-news.laohu8.com/highlight/detail?id=2484683741","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484683741?lang=zh_cn&edition=full","pubTime":"2024-11-20 15:30","pubTimestamp":1732087800,"startTime":"0","endTime":"0","summary":"[大手成交]信达生物(01801)在下午03:30出现大手买入，成交量为14.45万，成交价为港币$38.8，涉资560.66万。至目前为止，股价升7.939%，今日最高价为$38.95，而最低价为$35.55，总成交量为1.929千万股，总成交金额港币$7.363亿。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126132515779_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126132515779_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2411205379/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["01801","BK1589","LU2488822045.USD","BK1161","LU2328871848.SGD","BK1583","LU1969619763.USD"],"gpt_icon":0},{"id":"2484630151","title":"瑞银：维持信达生物(01801)“买入”评级 目标价上调至61.4港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2484630151","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484630151?lang=zh_cn&edition=full","pubTime":"2024-11-20 14:33","pubTimestamp":1732084383,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞银发布研究报告称，将信达生物(01801)目标价由60.7港元上调至61.4港元，维持“买入”评级。报告中称，在新型降血糖治疗药物GLP1最近问世之前，在没有便捷、可负担且有效的治疗下，估计内地超重或肥胖症人士当中仅0.1%接受临床治疗。GLP-1的临床测试结果及正面回馈，料显著渗透减肥市场及第二型糖尿病市场，该药在后者已有14%市占率。该行预测，信达生物玛仕度肽料在2034年取得中国GLP-1市场18%的市占率，基于该药的三项优势，包括预期期将在明年上半年为首个双目标GLP-1药物获准用于减肥用途，临床测试展示良好效用及安全性，以及公司强劲的商业化能力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1213331.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01801"],"gpt_icon":0},{"id":"2484543531","title":"港股信达生物一度涨8.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484543531","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484543531?lang=zh_cn&edition=full","pubTime":"2024-11-20 14:29","pubTimestamp":1732084171,"startTime":"0","endTime":"0","summary":"港股信达生物一度涨8.5%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202411203245476145.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411203245476145.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["HSTECH","LU2328871848.SGD","YANG","BK1583","01801","LU1969619763.USD","07226","BK1161","HSCEI","BK1589","LU2488822045.USD"],"gpt_icon":0},{"id":"2484536154","title":"信达生物：2034 年或占中国 GLP-1 市场 18% 买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2484536154","media":"和讯网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484536154?lang=zh_cn&edition=full","pubTime":"2024-11-20 12:16","pubTimestamp":1732076160,"startTime":"0","endTime":"0","summary":"【11 月 20 日，瑞银发布报告】瑞银报告指出，在新型降血糖治疗药物 GLP1 出现前，内地超重或肥胖症人士中仅 0.1%接受临床治疗。GLP-1 临床测试结果及反馈良好，将显著渗透减肥与第二型糖尿病市场，其在后者已有 14%市占率。报告预测，信达生物玛仕度肽料在 2034 年获中国 GLP-1 市场 18%市占率，因该药有三项优势，包括预期明年上半年成为首个双目标 GLP-1 药物用于减肥，临床测试效用及安全性良好，以及公司商业化能力强。该行将信达生物目标价由 60.7 港元调至 61.4 港元，维持“买入”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120144449abd1337c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120144449abd1337c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01801"],"gpt_icon":0},{"id":"2484387401","title":"信达生物持续涨逾7% 减重版司美格鲁肽正式在中国上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2484387401","media":"新浪港股","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484387401?lang=zh_cn&edition=full","pubTime":"2024-11-20 10:19","pubTimestamp":1732069146,"startTime":"0","endTime":"0","summary":"信达生物（01801）早盘持续上扬，股价上涨6.83%，现报38.35港元，成交额2.74亿港元。\n　　全球首个用于长期体重管理的胰高糖素样肽-1受体激动剂（GLP-1）周制剂诺和盈在上海复旦大学附属中山医院开出全国首批处方。据悉，6月25日，国家药品监督管理局（NMPA）批准了诺和盈在中国的上市申请。11月17日，诺和诺德宣布，减重版司美格鲁肽正式在国内商业化上市。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-11-20/doc-incwspwq8307206.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-11-20/doc-incwspwq8307206.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["BK1161","BK1583","LU2488822045.USD","LU1969619763.USD","BK1589","LU2328871848.SGD","01801"],"gpt_icon":0},{"id":"1138351797","title":"港股生物医药股集体走强，来凯医药-B大涨10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1138351797","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138351797?lang=zh_cn&edition=full","pubTime":"2024-11-20 10:16","pubTimestamp":1732068965,"startTime":"0","endTime":"0","summary":"11月20日，港股生物医药股集体走强，$来凯医药-B(02105)$涨10%，$荣昌生物(09995)$涨超8%，$信达生物(01801)$、$云顶新耀-B(01952)$涨超7%。","market":"hk","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07226","BK1161","01952","BK1574","HSCEI","09995","BK1583","BK1589","LU2328871848.SGD","01801","HSTECH","LU1969619763.USD","02105","LU2488822045.USD","YANG"],"gpt_icon":0},{"id":"2484180900","title":"港股异动 | 信达生物(01801)现涨超5% 减重版司美格鲁肽中国上市 玛仕度肽减重适应症有望明年获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2484180900","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484180900?lang=zh_cn&edition=full","pubTime":"2024-11-20 09:56","pubTimestamp":1732067807,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，信达生物现涨超5%，截至发稿，涨5.29%，报37.8港元，成交额1.46亿港元。消息面上，全球首个用于长期体重管理的胰高糖素样肽-1受体激动剂周制剂诺和盈在上海复旦大学附属中山医院开出全国首批处方。据悉，6月25日，国家药品监督管理局批准了诺和盈在中国的上市申请。11月17日，诺和诺德宣布，减重版司美格鲁肽正式在国内商业化上市。据悉，信达生物的GLP-1/GCG双重激动剂玛仕度肽走在国产GLP-1创新药的前列。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1213245.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1583","LU2488822045.USD","LU2328871848.SGD","BK1589","01801","LU1969619763.USD"],"gpt_icon":0},{"id":"2484180199","title":"信达生物(01801)上涨5.29%，报37.8元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2484180199","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484180199?lang=zh_cn&edition=full","pubTime":"2024-11-20 09:55","pubTimestamp":1732067745,"startTime":"0","endTime":"0","summary":"11月20日，信达生物(01801)盘中上涨5.29%，截至09:55，报37.8元/股，成交1.42亿元。信达生物主要致力于研发、生产和销售针对肿瘤、自身免疫、代谢、眼科等重大疾病领域的创新药物，已成功上市10个产品，同时有4个品种在审评中，4个新药分子进入III期或关键性临床研究，另有18个新药品种已入临床研究。至2023年10月，其患者援助项目已惠及17余万患者，药物捐赠总价值达34亿人民币。截至2024年中报，信达生物营业总收入39.52亿元、净利润-3.93亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/20095545475436.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","01801","LU1969619763.USD","BK1583","BK1589","LU2328871848.SGD","LU2488822045.USD"],"gpt_icon":0},{"id":"2484231138","title":"信达生物盘中异动 早盘急速拉升5.29%报37.800港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2484231138","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484231138?lang=zh_cn&edition=full","pubTime":"2024-11-20 09:55","pubTimestamp":1732067741,"startTime":"0","endTime":"0","summary":"2024年11月20日早盘09时55分，信达生物股票出现异动，股价急速上涨5.29%。截至发稿，该股报37.800港元/股，成交量381.131万股，换手率0.23%，振幅6.27%。信达生物股票所在的药品行业中，整体涨幅为0.30%。其相关个股中，精优药业、信达生物、中智药业涨幅较大，振幅较大的相关个股有精优药业、信达生物、凯莱英，振幅分别为39.58%、5.99%、4.84%。利妥昔单抗生物类似药IBI-301,用于治疗非霍奇金淋巴瘤及慢性淋巴细胞白血病。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120095541abd0a954&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120095541abd0a954&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","01801","BK1589","BK1161","LU2488822045.USD","LU1969619763.USD","LU2328871848.SGD"],"gpt_icon":0},{"id":"2484180150","title":"港股医药股走强 信达生物涨超4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484180150","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484180150?lang=zh_cn&edition=full","pubTime":"2024-11-20 09:52","pubTimestamp":1732067571,"startTime":"0","endTime":"0","summary":"每经AI快讯，港股医药股走强，截至发稿，信达生物(01801.HK)涨4.18%、中智药业(03737.HK)涨3.33%、凯莱英(06821.HK)涨2.42%、和黄医药(00013.HK)涨2.28%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202411203245172335.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411203245172335.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1583","LU2488822045.USD","01801","BK1589","LU2328871848.SGD","LU1969619763.USD"],"gpt_icon":0},{"id":"2484509265","title":"概念掘金 | 司美格鲁肽减肥药正式在中国上市，多家电商平台已上线","url":"https://stock-news.laohu8.com/highlight/detail?id=2484509265","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484509265?lang=zh_cn&edition=full","pubTime":"2024-11-17 14:35","pubTimestamp":1731825344,"startTime":"0","endTime":"0","summary":"市场前景广阔","market":"us","thumbnail":"https://img3.gelonghui.com/06664-7e9dde8e-9f54-49fb-a50c-81a04f916999.jpg?guru_height=853&guru_width=1280","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/06664-7e9dde8e-9f54-49fb-a50c-81a04f916999.jpg?guru_height=853&guru_width=1280"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/1336126","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK0077","BK4585","LU2148510915.USD","LU0405327494.USD","BK0201","BK0028","BK0183","BK0251","LU1064131003.USD","LU1093756168.USD","LU1093756325.SGD","LU0405327148.USD","LU2488822045.USD","600276","300003","LU1328615791.USD","NVO","688117","BK0239","BK0114","BK0188","BK0012","IE00BKVL7J92.USD","BK0042","BK4588","002821","BK0196","BK0070","01801","BK0060","BK0113","603456","BK0132","LU0154236417.USD","IE00BZ1G4Q59.USD","300199","BK4007","LU1064130708.USD","688076","BK4532"],"gpt_icon":1},{"id":"2483040348","title":"信达生物11月15日主力资金流出217万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2483040348","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483040348?lang=zh_cn&edition=full","pubTime":"2024-11-15 16:15","pubTimestamp":1731658529,"startTime":"0","endTime":"0","summary":"11月15日, 信达生物股价跌1.33%，报收37.20元，成交金额2.32亿元，换手率0.38%，振幅4.51%，量比0.47。信达生物今日主力资金净流出217万元，连续3日净流出，上一交易日主力净流出1305万元，今日环比减少83.37%。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为66.67%，平均跌幅为1.43%。该股近5个交易日下跌4.25%，主力资金累计净流出3077万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流入1.09亿元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115161548a23a5650&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115161548a23a5650&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","LU2488822045.USD","BK1589","01801","LU1969619763.USD","LU2328871848.SGD","BK1583"],"gpt_icon":0},{"id":"2483849639","title":"信达生物(01801)上涨2.02%，报37.9元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2483849639","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483849639?lang=zh_cn&edition=full","pubTime":"2024-11-14 15:48","pubTimestamp":1731570505,"startTime":"0","endTime":"0","summary":"11月14日，信达生物(01801)盘中上涨2.02%，截至15:48，报37.9元/股，成交3.32亿元。信达生物主要致力于研发、生产和销售针对肿瘤、自身免疫、代谢、眼科等重大疾病领域的创新药物，已成功上市10个产品，同时有4个品种在审评中，4个新药分子进入III期或关键性临床研究，另有18个新药品种已入临床研究。至2023年10月，其患者援助项目已惠及17余万患者，药物捐赠总价值达34亿人民币。截至2024年中报，信达生物营业总收入39.52亿元、净利润-3.93亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/14154845287527.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU2328871848.SGD","LU2488822045.USD","01801","BK1589","LU1969619763.USD","BK1583","BK1161"],"gpt_icon":0},{"id":"2483900031","title":"关联交易惹争议 “认错”后信达生物还需一个新故事","url":"https://stock-news.laohu8.com/highlight/detail?id=2483900031","media":"首财研究院","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483900031?lang=zh_cn&edition=full","pubTime":"2024-11-12 20:31","pubTimestamp":1731414707,"startTime":"0","endTime":"0","summary":"生生不息，不期而遇！点击上方蓝字关注深度 客观 穿透下一个价值跳板是什么作者：闻道编辑：陈晨风品：张戈来源：首财——首条财经研究院知错就改，善莫大焉。11月3日，信达生物宣布，与Lostrancos终止10月25日官宣的认购协议，称此举经过双方进一步考虑后达成。从官宣认购到终止交易时隔不到两周，看似有些戏谑，实则源于...","market":"hk","thumbnail":"https://inews.gtimg.com/om_ls/OtsWTGUYuo3UwEOUjsK2KvI7YMzEHi2qJoRhZIb-J6ixcAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OtsWTGUYuo3UwEOUjsK2KvI7YMzEHi2qJoRhZIb-J6ixcAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20241112A08XS100","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20241112A08XS100","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["LU1969619763.USD","LU2488822045.USD","LU2328871848.SGD","BK1589","BK1583","BK1161","01801"],"gpt_icon":0},{"id":"2482726126","title":"信达生物(01801)上涨2.01%，报38.05元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2482726126","media":"金融界","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482726126?lang=zh_cn&edition=full","pubTime":"2024-11-12 15:47","pubTimestamp":1731397628,"startTime":"0","endTime":"0","summary":"11月12日，信达生物(01801)盘中上涨2.01%，截至15:47，报38.05元/股，成交4.73亿元。信达生物主要致力于研发、生产和销售针对肿瘤、自身免疫、代谢、眼科等重大疾病领域的创新药物，已成功上市10个产品，同时有4个品种在审评中，4个新药分子进入III期或关键性临床研究，另有18个新药品种已入临床研究。至2023年10月，其患者援助项目已惠及17余万患者，药物捐赠总价值达34亿人民币。截至2024年中报，信达生物营业总收入39.52亿元、净利润-3.93亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/12154745190762.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1589","LU2488822045.USD","BK1161","LU1969619763.USD","01801","LU2328871848.SGD","BK1583"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.innoventbio.com","stockEarnings":[{"period":"1week","weight":0.0212},{"period":"1month","weight":-0.1575},{"period":"3month","weight":-0.1139},{"period":"6month","weight":0.0724},{"period":"1year","weight":-0.0931},{"period":"ytd","weight":-0.0994}],"compareEarnings":[{"period":"1week","weight":0.0085},{"period":"1month","weight":-0.0438},{"period":"3month","weight":0.1129},{"period":"6month","weight":0.0533},{"period":"1year","weight":0.1052},{"period":"ytd","weight":0.1498}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"信达生物制药是一家主要从事生物制药的投资控股公司。该公司及其子公司从事抗体及蛋白质医药产品的研发、药品的销售及分销，以及提供咨询及研发服务。该公司的主要产品为达伯舒（信迪利单抗注射液），用于治疗复发或难治性经典霍奇金淋巴瘤。该公司的产品还包括阿达木单抗生物类似药IBI-303，用于治疗类风湿性关节炎、强直性脊柱炎及银屑病。贝伐珠单抗生物类似药IBI-305，用于治疗转移性结直肠癌及晚期、转移性或复发性非小细胞肺癌（NSCLC）。利妥昔单抗生物类似药IBI-301，用于治疗非霍奇金淋巴瘤及慢性淋巴细胞白血病。该公司的产品应用于肿瘤、代谢、免疫学及眼底病等领域。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.049204},{"month":2,"riseRate":0.666667,"avgChangeRate":0.101831},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.050735},{"month":4,"riseRate":0.666667,"avgChangeRate":0.022046},{"month":5,"riseRate":0.333333,"avgChangeRate":0.006538},{"month":6,"riseRate":0.666667,"avgChangeRate":0.118103},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.029935},{"month":8,"riseRate":0.833333,"avgChangeRate":0.002206},{"month":9,"riseRate":0.666667,"avgChangeRate":0.03832},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.010418},{"month":11,"riseRate":0.571429,"avgChangeRate":0.078612},{"month":12,"riseRate":0.5,"avgChangeRate":0.07208}],"exchange":"SEHK","name":"信达生物","nameEN":"INNOVENT BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信达生物,01801,信达生物股票,信达生物股票老虎,信达生物股票老虎国际,信达生物行情,信达生物股票行情,信达生物股价,信达生物股市,信达生物股票价格,信达生物股票交易,信达生物股票购买,信达生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}